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Chloral Hydrate (CH) is a sedative and hypnotic drug used in pediatric procedures owing to the 
low depressive effect it has on the respiratory and cardiac systems. 
Aim: To assess the efficacy of the drug in performing ABR and to systematize its use. 
Materials and Methods: A prospective cross-sectional study with 41 children without history of 
heart or lung disease. The initial dose of CH at 10% was 50mg/Kg, with a boost dose of 6mg/Kg 
administered 30 minutes later in cases in which there was no sedation. Drug effectiveness was 
established by sleep induction by 1 hour after the administration of the initial dose. Sleep occurrence 
was correlated with doses (50mg or 56mg/Kg), age, weight and gender. 
Results: All the 41 children who participated in the study took 50mg/kgof the agent and 23 of them 
slept within 30 minutes, 2 had respiratory complications, 16 had the 6mg/Kg boost dose and 13 
fell asleep after 30 minutes. The 56 mg/kg dose presented a statistically significant effect on sleep 
induction (p<0.05) when compared to the 50mg/kg dose. 
Conclusion: CH produced a satisfactory effect with 50 mg/Kg dose plus 6mg/kg up to one hour 
after administration. Complications can occur regardless of the dose used. 
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INTRODUCTION
Chloral hydrate (CH) is a well established sedative 
and hypnotic drug used in pediatric and dental patients 
because of its little depressive effect on the respiratory and 
cardiac systems1. Nonetheless, cardiac arrhythmias and 
sudden death in children, especially those with obstructi-
ve apnea are described in the literature2, mainly with the 
use of high doses, very likely because of the build up of 
serum trichloroethanol, an intermediate metabolite from 
the liver metabolism of the drug1. A possible carcinogenic 
action, already seen in guinea pigs has been described3, 
although not proven in humans1.
Among the less severe complications we have 
paradoxical hyperactivity, nausea, vomits and excessive 
sleepness2.
CH is one of the drugs of choice for the sedation of 
children submitted to Brainstem Auditory Evoked Poten-
tials (BAEP), when any movement or muscle contraction 
can generate artifacts which impact on the analysis4.
A deep sleep with mean duration of one hour is 
quickly induced depending on the dose used, not leaving 
residual sleepiness after this period; nonetheless, there is 
no consensus in the literature as to the best dose, which 
can vary between 40 and 100mg/kg2,4-7. Thus, we did this 
study in order to assess the efficacy of CH as a sedative 
agent used in the BAEP study in children and systematize 
its employment in daily practice.
MATERIALS AND METHODS
This research project was approved by the Ethics in 
Research Committee of our institution (protocol 297/2008).
We did a cross-sectional prospective study with 41 
children, without prior severe pulmonary or heart disea-
ses, between 01 and 11 years; mean age of 3.75 years and 
standard deviation of ± 2.25 years, where 46.34% were 
females and 53.66% were males, consecutively referred 
to BAEP study under sedation.
We included only those children who failed in 
their tests under natural sleep or those with body weight 
below 30kg. CH was contraindicated in those children 
with heart diseases and/ or severe pulmonary diseases by 
their clinicians, and it was also contraindicated in those 
children using central nervous system drugs who were 
not approved for the procedure by their neurologist and/
or psychiatrist.
All the participants had been fasting for at least 6 
hours and were recommended sleep deprivation in order 
to facilitate drug action.
The initial dose of CH at 10% was 50mg/kg with 
a booster of 6mg/kg given after 30 minutes in the cases 
when there was no sedation. The patients were monitored 
through a pulse oxymeter and the procedure room was 
equipped to care for respiratory complications (oropha-
ryngeal cannula, valve-mask bag with oxygen reservoir, 
pediatric facial mask, pediatric endotracheal tube, laryngos-
cope with straight and curved blades, aspiration cannula, 
nasal catheter, material for venous access and medication 
to treat respiratory arrest).
The drug effectiveness was established by sleep 
induction up to one hour after administering the initial 
dose. Sleep was correlated with the 50mg or 56mg/kg 
doses, with the age ranges of < 2 years, from 2 to 5 years 
and > 5 years), in the following weight ranges <13Kg, 
from 13 to 19Kg and >19Kg) and with gender, using the 
pertaining statistical tests and statistical analyses (Levene 
test: test comparing two or more populations according 
with variance homogeneity, and chi-square test for samples 
with nominal variables in two or more categories) and a 
significance level of 5%.
RESULTS
All the 41 children who participated in the study 
took 50mg/kg and 23 slept within 30 minutes. Two children 
(4.88%) had respiratory complications with reduction in 
the level of blood oxygen (<90%) still sleepy but awake. 
Desaturation was quickly reverted with an increase in 
oxygen supply through a facial mask and the protocol 
was suspended. 16 children took a booster dose of 6mg/
kg (total of 56mg/kg) and 13 slept for 30 minutes more. 
The 50mg/kg dose, followed by 6mg/kg had a statistically 
significant effect on the induction of sleep when compared 
to the 50mg/kg dose (p<0.05).
There was no significant correlation between sleep 
induction and age (p=0.170), between sleep induction and 
weight (p= 0.51) and between sleep induction and gender 
(p= 0.142). Figure 1 depicts a perception map comparing 
the variables associated with the sample, in other words, 
Figure 1. Perception map of the variables associated with age ranges, 
weight ranges and whether or not there was a booster dose with sa-
tisfactory effect or not.
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age ranges, whether or not the 6mg/kg booster dose was 
used and if the effect was satisfactory (sleep induction) or 
not. The result indicated that there is no visible associa-
tion between the respective variables when analyzed in 
a combined fashion since, in the graph, they do not form 
clusters among the different points which represent each 
variable mentioned.
DISCUSSION
Although CH is one of the drugs of choice to se-
date children to be submitted to ENT procedures, such as 
nasofibroscopy5 and BAEP, very little is discussed about 
its effective dose and its side effects. CH is metabolized 
into trichloroethanol which is responsible for the acute 
toxicity of this drug. The trichloroethanol has a half life 
of 9 to 40 hours, depending on patient age and the body 
development. Trichloroacetic acid is still detected 6 days 
after administration of one single dose of 50mg/kg3 . The-
refore, in the cases of sedation failure in the performance 
of the exam or the need to repeat the procedure, we do 
not recommend a new CH administration within less than 
a week of interval.
The major advantage of CH is a relatively fast se-
dation induction, especially when associated with sleep 
deprivation and, producing no residual sleepiness after 
this period, enabling each child to be quickly awakened 
only by increasing external stimuli, which is a different 
effect from that of other drugs that cause Central Nervous 
System depression2. Nonetheless, literature suggests that 
CH is chosen as the sedation drug of choice for procedures 
in children below 46 months of age only and that, after 
this age, another agent must be used in order to provide 
a safe sedation effect considering some toxic effects2.
We agree with the literature in keeping the ma-
ximum weight range in 30kg, however, because of the 
impossibility of using other CNS depressive drugs in our 
service, we have used CH in older children. Our results do 
not show statistical differences comparing the satisfactory 
effect, in other words, sleep induction, with the age of the 
patients for both doses of 50mg/kg and 56mg/kg. we also 
did not find significant results comparing sedation with 
gender and weight in our sample, but we reinforce that 
we did not administer CH at the dose of 50mg/kg and/or 
56mg/kg for children heavier than 30kg.
Sleep induction with the total dose of 56mg/kg was 
statistically more significant when compared to the 50mg/
kg dose, despite the sample with a lower dose be larger 
and, even with the literature recommending doses between 
40 and 100mg/kg2,4-7, we believe that the 56mg/kg dose - 
within the proposed protocol of first giving 50mg/kg and 
if needed a 6mg/kg booster dose, yields good results, not 
requiring larger doses.
Two children (4.88% of the sample) had respiratory 
depression (<90% of saturation) with the 50 mg/kg dose 
reverted with oxygen given through a facial mask. This 
percentage is very close to the one reported in the litera-
ture (5.3%) even with larger samples (854 patients)8 and 
with doses considered safe (65± 13mg/kg). Most of these 
types of complications can be solved by increasing the 
flow of oxygen through the facial mask or nasal catheter, 
nonetheless, more invasive procedures may be needed. 
Because of these possible adverse effects, it is mandatory 
to have, in the exam room, the minimum necessary equi-
pment to treat respiratory depression, besides a physician 
properly trained to care for such complication8.
In all cases of respiratory complications, it is highly 
recommended to suspend the procedure for a better con-
trol of the patient and that is why we did not continue 
with the protocol concerning the two children who had 
oxygen desaturation. It is also worth stressing that adver-
se respiratory events may happen even after the end of 
the procedure8 and with the child awake in the recovery 
room. Thus, we recommend monitoring the child for at 
least one hour after the end of sedation.
Complications such as paradoxical restlessness are 
described and present in about 2% of the patients who 
received CH, although we did not notice these adverse 
effects in this specific sample. Other complications asso-
ciated with the use of CH such as hypotension, bradychar-
dia and supraventricular tachycardia are described in the 
cases of sedation for invasive procedures  such as cardiac 
catheterization and in children with high anesthetic risk 
(ASA III and IV)8.
CONCLUSION
We can then conclude that the protocol proposed 
for the total dose of 56mg/kg (50 mg/kg followed by a 
booster dose of 6mg/kg) proved to be more effective in 
the sedation with only the 50 mg/kg dose and that this 
booster must be considered for those cases in which se-
dation did not happen within 30 minutes after 50mg/kg 
of CH administration. Adverse events such as respiratory 
complications may happen regardless of the dose used, 
requiring patient monitoring and proper equipment for 
emergency care.
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